Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Wagner KR, Abdel-Hamid HZ, Mah JK, Campbell C, Guglieri M, Muntoni F et al (2020) Randomized phase 2 trial and open-label extension of Domagrozumab in Duchenne muscular dystrophy
have provided evidence that tofacitinib directly modulates mitochondrial function, such as regulating key mitochondrial genes, increasing oxidative phosphorylation, enhancing ATP production while diminishing glycolytic flow and key glycolytic genes (162)
For more information, please visit: For more information, please visit: The issuer is solely responsible for the content of this announcement.
It is also more costly and may not be necessary for everyone
Xultophy European Public Assessment Report
